News of Note—Pfizer results, GSK shortage and more

In this week's news of note, Pfizer's Prevnar posted a third-quarter sales increase due to government purchases. (Pixabay)

Here is some other vaccine news of note for the week:

> Pfizer's vaccine sales in the third quarter grew 12% to $1.85 billion. Prevnar 13 sales in the U.S. were up 12% due to the timing of government purchases. Release (PDF)

> Pharmacists in Canada are reporting a shortage of GlaxoSmithKline's hep A and B vaccine for travelers Twinrix. CBC article

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

> A subsidiary of South Korea's GC Pharma received approval to start phase 1 testing of a shingles vaccine. Release

> Enesi Pharma entered an R&D deal to work on vaccines against Chikungunya, Zika and peanut allergy. Release

Suggested Articles

An FDA panel gave Sanofi's Dengvaxia a mixed endorsement, voting down its use in people 17 and older.

Prosecutors in the Philippines have found probable cause to indict six Sanofi officials for its Dengvaxia rollout.

The FDA has issued guidance on continuous manufacturing and is allocating $58 million to move forward advanced manufacturing processes.